© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
September 14th 2021, 7:00pm
Eating or drinking less than 1 hour before bedtime was associated with increased risk of wake after sleep onset, a key symptom of chronic insomnia that significantly correlates with poor sleep quality.
September 11th 2021, 3:00pm
Adherence to continuous positive airway pressure (CPAP) resulted in a large decrease in insomnia and a significant reduction in prevalence of insomnia from baseline to follow-up in patients with obstructive sleep apnea.
September 7th 2021, 7:45pm
Each additional hour spent outside during the day was associated with lower odds of later sleep-, mood-, and circadian-related adverse outcomes.
August 27th 2021, 3:00pm
A roundup of the latest news in sleep research reported across MJH Life Sciences™.
August 24th 2021, 4:00pm
Patients with comorbid Alzheimer disease and insomnia were found to be more likely to report claims of higher cost health care services such as inpatient hospitalization and emergency care, along with significantly greater mean total annual health care costs than those without insomnia.
August 18th 2021, 9:00am
The scientific statement addresses current knowledge regarding the impact of obstructive sleep apnea on the cardiovascular health of children and adolescents, as well as best practices to evaluate symptoms.
August 15th 2021, 6:00pm
August 12th 2021, 9:00pm
Jazz Pharmaceuticals’ Xywav oral solution is the first treatment to be approved for adults with idiopathic hypersomnia.
August 12th 2021, 5:30pm
Results of the phase 3 REST-ON study exhibited significant improvement in patients with narcolepsy treated with once-nightly sodium oxybate, FT218, versus placebo.
August 7th 2021, 12:00pm
Relaxed social and professional constraints brought on by pandemic-related lockdowns benefitted the sleep schedules of patients with central hypersomnias.